Ligand Pharmaceuticals, Inc. (LGNZZ)

Ligand Pharmaceuticals, Inc. (LGNZZ) — VMCI valuation read

The headline on Ligand Pharmaceuticals, Inc. (LGNZZ) is a 58/100 VMCI score, set against a Healthcare sector median of 50. That 8-point above-median read reflects the five-pillar weighting and, for a mid-cap name, suggests a relative-value tailwind is in the data.

LGNZZ insider activity report: 0 buys, 0 sells filed via Form 4 over the past 30 days. The next datable items are the 10-Q schedule and any 8-K-triggering events; both feed the VMCI Integrity pillar more than the price tape.

**Investor frame.** LGNZZ trades at 21.0x earnings, 17% above the Healthcare median of 18.0x sets the value side. ROIC of 11.0% sits 1.0pp above the Healthcare median (10.0%) sets the quality side. Net debt to EBITDA of 0.0x leaves covenant headroom sets the risk side, the three lines a value buyer reads first on LGNZZ.

LGNZZ rose 1.6% over the trailing 7 days, with a -11.5% read on a 30-day basis.